Kelly K - Search Results

1

Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity.

Fernández B, Chittoor-Vinod VG, Kluss JH, Kelly K, Bryant N, Nguyen APT, Bukhari SA, Smith N, Lara Ordóñez AJ, Fdez E, Chartier-Harlin MC, Montine TJ, Wilson MA, Moore DJ, West AB, Cookson MR, Nichols RJ, Hilfiker S. Fernández B, et al. Among authors: kelly k. J Parkinsons Dis. 2022;12(5):1423-1447. doi: 10.3233/JPD-213128. J Parkinsons Dis. 2022. PMID: 35599495 Free PMC article.

2

Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.

Nguyen APT, Tsika E, Kelly K, Levine N, Chen X, West AB, Boularand S, Barneoud P, Moore DJ. Nguyen APT, et al. Among authors: kelly k. Proc Natl Acad Sci U S A. 2020 Jul 21;117(29):17296-17307. doi: 10.1073/pnas.1922184117. Epub 2020 Jul 6. Proc Natl Acad Sci U S A. 2020. PMID: 32631998 Free PMC article.

3

Exosome markers of LRRK2 kinase inhibition.

Wang S, Kelly K, Brotchie JM, Koprich JB, West AB. Wang S, et al. Among authors: kelly k. NPJ Parkinsons Dis. 2020 Nov 13;6(1):32. doi: 10.1038/s41531-020-00138-7. NPJ Parkinsons Dis. 2020. PMID: 33298972 Free PMC article.

4

Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics.

Kelly K, West AB. Kelly K, et al. Front Neurosci. 2020 Aug 6;14:807. doi: 10.3389/fnins.2020.00807. eCollection 2020. Front Neurosci. 2020. PMID: 32903744 Free PMC article. Review.

5

Genetic background influences LRRK2-mediated Rab phosphorylation in the rat brain.

Kelly K, Chang A, Hastings L, Abdelmotilib H, West AB. Kelly K, et al. Brain Res. 2021 May 15;1759:147372. doi: 10.1016/j.brainres.2021.147372. Epub 2021 Feb 15. Brain Res. 2021. PMID: 33600829 Free PMC article.

6

Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of α-synuclein.

Brzozowski CF, Hijaz BA, Singh V, Gcwensa NZ, Kelly K, Boyden ES, West AB, Sarkar D, Volpicelli-Daley LA. Brzozowski CF, et al. Among authors: kelly k. Acta Neuropathol Commun. 2021 Nov 8;9(1):180. doi: 10.1186/s40478-021-01283-7. Acta Neuropathol Commun. 2021. PMID: 34749824 Free PMC article.

7

Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain.

Xu E, Boddu R, Abdelmotilib HA, Sokratian A, Kelly K, Liu Z, Bryant N, Chandra S, Carlisle SM, Lefkowitz EJ, Harms AS, Benveniste EN, Yacoubian TA, Volpicelli-Daley LA, Standaert DG, West AB. Xu E, et al. Among authors: kelly k. Mol Neurodegener. 2022 Jan 10;17(1):7. doi: 10.1186/s13024-021-00509-5. Mol Neurodegener. 2022. PMID: 35012605 Free PMC article.

8

The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition.

Kelly K, Wang S, Boddu R, Liu Z, Moukha-Chafiq O, Augelli-Szafran C, West AB. Kelly K, et al. Exp Neurol. 2018 Nov;309:1-13. doi: 10.1016/j.expneurol.2018.07.012. Epub 2018 Jul 24. Exp Neurol. 2018. PMID: 30048714 Free PMC article.

9

Heterogeneity in α-synuclein fibril activity correlates to disease phenotypes in Lewy body dementia.

Sokratian A, Ziaee J, Kelly K, Chang A, Bryant N, Wang S, Xu E, Li JY, Wang SH, Ervin J, Swain SM, Liddle RA, West AB. Sokratian A, et al. Among authors: kelly k. Acta Neuropathol. 2021 Apr;141(4):547-564. doi: 10.1007/s00401-021-02288-1. Epub 2021 Feb 28. Acta Neuropathol. 2021. PMID: 33641009 Free PMC article.

10

Evaluation of ABT-888 in the amelioration of α-synuclein fibril-induced neurodegeneration.

Hastings L, Sokratian A, Apicco DJ, Stanhope CM, Smith L, Hirst WD, West AB, Kelly K. Hastings L, et al. Among authors: kelly k. Brain Commun. 2022 Feb 22;4(2):fcac042. doi: 10.1093/braincomms/fcac042. eCollection 2022. Brain Commun. 2022. PMID: 35282165 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,624 results

Search Page